Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study.
CONCLUSION: Sorafenib use should be limited to patients with Child A, PS 0-1, and low disease burden.
PMID: 29124987 [PubMed - as supplied by publisher]
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research
More News: Cancer & Oncology | Carcinoma | Children | Cirrhosis | Egypt Health | Gastroenterology | Hepatocellular Carcinoma | Liver | Liver Cancer | Study | Toxicology | Urology & Nephrology